Telomir Pharmaceuticals, Inc. is a pre-clinical-stage pharmaceutical company. The Company is focused on the development of Telomir-1, a novel small molecule metal ion chelator and regulator designed to lengthen the DNA’s protective telomere caps, which are crucial in the aging process. Telomir 1 is being developed to protect stem cells by elongating and stimulating the telomeres to sustain self-renewal. Telomir-1 helps protect against age-related conditions, including Progeria (a rare genetic disorder that causes rapid aging in children), Wilson’s disease (a genetic disorder leading to toxic copper buildup in the body), and age-related macular degeneration (AMD), as well as Type 2 Diabetes, cancer, and Alzheimer’s disease. It is exploring the potential of Telomir-1 with ongoing research in animals and then in humans. It is focused on developing and commercializing TELOMIR-1, proposed to be dosed orally, with the aim of promoting longevity and enhancing overall quality of life.
종목 코드 TELO
회사 이름Telomir Pharmaceuticals Inc
상장일Feb 09, 2024
CEOAminov (Erez)
직원 수- -
유형Ordinary Share
회계 연도 종료Feb 09
주소900 West Platt Street, Suite 200
도시TAMPA
증권 거래소NASDAQ OMX - NASDAQ BASIC
국가United States of America
우편 번호33606
전화18138642562
웹사이트https://telomirpharma.com/
종목 코드 TELO
상장일Feb 09, 2024
CEOAminov (Erez)
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.

데이터 없음